Status:
COMPLETED
The Spleen in Sickle Cell Anemia and Sickle Cell Thalassemia
Lead Sponsor:
HaEmek Medical Center, Israel
Conditions:
Sickle Cell Anemia
Thalassemia
Eligibility:
All Genders
1-35 years
Brief Summary
The spleen in Sickle Cell Anemia and Sickle Cell Thalassemia is usually enlarged in the first years of life but the immune protection provided is considered insufficient. In homozygous Sickle cell pat...
Detailed Description
Clinical and laboratory characteristics related to the spleen in SCA patients will be studied. Two groups of patient will be compared, a group of Sickle cell patients (Homozygous) and a second group ...
Eligibility Criteria
Inclusion
- All the patients followed up at the Pediatric Hematology Unit
Exclusion
- Patients lost from follow up of with insufficient data
Key Trial Info
Start Date :
February 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 1 2010
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00971698
Start Date
February 1 2009
End Date
August 1 2010
Last Update
August 26 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pediatric Hematology Unit and Pediatric Dpt B - HaEmek Medical Center
Afula, Israel, 18101